Quick Takeaways
- MPM BioImpact LLC filed SCHEDULE 13G/A for Compass Therapeutics, Inc. Common Stock, par value $0.001 per share (CMPX).
- Disclosed ownership: 4.1%.
- Date of event: 30 Jun 2025.
MPM BioImpact LLC - 30 Jun 2025 SCHEDULE 13G/A Report for Compass Therapeutics, Inc. Common Stock, par value $0.001 per share (CMPX)
- Filing Manager
- MPM BioImpact LLC
- Reporting Manager
- MPM BioImpact LLC
- Symbol
- CMPX
- Shares outstanding
- 137,134,268 shares
- Disclosed Ownership
- 5,622,505 shares
- Ownership
- 4.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Aug 2025, 16:29:56 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MPM BioImpact LLC disclosed 4.1% ownership in Compass Therapeutics, Inc. Common Stock, par value $0.001 per share (CMPX) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 12 Aug 2025, 16:29.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| MPM BioImpact LLC | 4.1% | 5,622,505 | 5,622,505 | 0 | /s/ Christopher Wolf | Chief Financial Officer |